iZafe Group AB Series B
The answer first
Does iZafe Group beat the market?
No, iZafe Group has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 1% of Nordic stocks
- Quality21
- Value2
- Trend5
No. 191 of 195 in healthcare
Max for seven days
Follow iZafe Group with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about iZafe Group
Your first answer is free, no account needed.
Do you own iZafe Group, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with iZafe Group and a few more. Free, no card.
Super Stock+44.6%In short
- iZafe Group has fallen 69.2% over the past year, including dividends.
- Overall, iZafe Group ranks better than 1% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 94.0%. The price is 98.7% below its peak now.
What do analysts think of iZafe Group?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 1% of Nordic stocks.
No. 191 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 168 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.03
- Asset turnoverSales divided by everything the company owns0.27
- Return on equityProfit divided by equity−218.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 180 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity6.8
- P/SPrice divided by sales9.1
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 174 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−38.8%
- 6 months−51.4%
- 9 months−51.4%
- 12 months−69.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own iZafe Group
2 funds we follow own iZafe Group. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About iZafe Group
iZafe Group AB Series B is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 14 employees.
iZafe Group AB (publ), a medical technology company, develops and markets medical and digital security solutions in Sweden and internationally. It offers Dosell, an automated medication dispenser for medication at home; and Pilloxa, an app for clinical studies, as well as to engage and involve patients. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.


See the full analysis of iZafe Group.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card